Study	Reason for exclusion
Gupta 2003	Study on immunogenicity and safety of HBV vaccine, comparisons of 2 doses HBV vaccine versus 3 doses in HBsAg negative pregnant women.
Li 2003	Study on 3 comparisons of HBIG versus lamivudine versus no treatment in HBsAg positive pregnant women for prevention of intrauterine infection of HBV.
Li 2004	Study on HBIG versus placebo in HBsAg positive pregnant women for prevention of intrauterine infection of HBV.
Patwardhan 2005	Study on HBV vaccine in both non‐pregnant and pregnant women for prevention of vertical transmission. Abstract only.
Wang 2008	Study on HBIG in HBsAg and HBeAg positive pregnant women for prevention of mother to infant HBV transmission.
Xu 2004	Study on lamivudine versus placebo in late pregnancy for mothers with high viremia, in addition to HBV vaccination plus HBIG for the infants for prevention of mother‐to‐child transmission of HBV.
Xu 2006	Study on HBIG versus placebo in HBeAg and HBsAg positive pregnant women for prevention of intrauterine infection of HBV.
Xu 2009	Study on lamivudine in highly viremic and late pregnancy for prevention of perinatal transmission of HBV infection.
Yu 2003	Study on HBIG in HBsAg positive pregnant women for prevention of intrauterine infection. This was an observational study.
Yuan 2006	Study on 3 doses of HBIG in seropositive for hepatitis B e antigen (HBeAg) pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV.
Yue 1999	Study on HBIG in seropositive for hepatitis B surface (HBsAg) antigen pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV.
Zhu 1997	Study on HBIG in HBV carriers pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV.
Zhu 2003	Study on 3 doses of HBIG in HBsAg carrier pregnant women versus no treatment for prevention of intrauterine transmission of HBV.

HBeAG: hepatitis B e antigen
 HBIG: hepatitis B immunoglobulin
 HBsAg: hepatitis B surface antigen
 HBV: hepatitis B virus